4 research outputs found
Clinical and laboratory characteristics of patients who developed myelosuppression during low-dose MTX.
<p>Clinical and laboratory characteristics of patients who developed myelosuppression during low-dose MTX.</p
Severity of myelosuppression related to low-dose MTX therapy for inflammatory rheumatic diseases (n = 40).
<p>Severity of myelosuppression related to low-dose MTX therapy for inflammatory rheumatic diseases (n = 40).</p
Factors associated with severity of MTX-related neutropenia (n = 37).
<p>Factors associated with severity of MTX-related neutropenia (n = 37).</p
Factors associated with severity of MTX-related pancytopenia (n = 31).
<p>Factors associated with severity of MTX-related pancytopenia (n = 31).</p